Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A tertiary amine with a muscarinic effect similar to atropine, used in the form of eye drops for pupil dilation (Akorn 2017, Alcon 2017)
Since the last update we have not found published data on its excretion in breastmilk.
There have been reports of serious side effects after ophthalmic administration in children (seizure in a premature baby girl: Büyükcam 2012).
A recent publication reports fewer side effects than atropine (Wakayama 2018)
Because of its anticholinergic effect it can inhibit the secretion of prolactin (Bizzarro 1980, Evans 1985) and reduce the production of milk during the first weeks after childbirth. When breastfeeding is well established, milk production depends less on the levels of prolactin.
The small dose and the low plasma absorption of most topical ophthalmological preparations make it unlikely it will transfer to breastmilk in significant amounts.
After its ophthalmic administration, plasma concentrations of cyclopentolate are in the order of few nanograms per millilitre and are about 3,000 times lower than ophthalmic concentrations (Hale 2017 p 238, Alcon 2017).
Use the minimum dose and concentration possible and press a finger on the conjunctival sac for 2 minutes, removing the excess with a clean cloth, in order to avoid systemic absorption.